DermTech (DMTK) has issued an announcement.
DermTech, Inc. and its subsidiary have filed for Chapter 11 bankruptcy, aiming to restructure their finances while continuing to operate and potentially sell their assets. Prior to this, the company reduced its workforce by 20% and entered into retention agreements with key executives, offering them substantial financial incentives to stay on until the end of 2024. Investors are cautioned that the company’s securities are now highly speculative and that equity holders could face complete loss, depending on the bankruptcy outcomes.
See more data about DMTK stock on TipRanks’ Stock Analysis page.
